Keywords: Prostate, Data Analysis, Biopsy Targeting, Lesion Identification, Risk Categorization
Motivation: The accurate localization and assessment of aggressiveness in patients with prostate cancer is key to appropriate treatment, especially radiation therapy (RT) planning.
Goal(s): To evaluate the performance of a Habitat Risk Scoring (HRS) system in MRI/Ultrasound-fused biopsy of prostate cancer at the time of the fiducial marker placement prior to RT.
Approach: The yield of significant prostate cancer biopsy findings under HRS guidance was compared with alternative standard techniques.
Results: Patients from the Miami BLaStM trial were analyzed with and without HRS guidance. The biopsies obtained through HRS guidance yielded more clinically significant cancer.
Impact: The implementation of the Habitat Risk Scoring (HRS) system in transperineal platform for MRI-US biopsies significantly improved the delineation of aggressive cancer. These volumes are integral to the safe delivery of focal escalated radiation doses.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords